Crossmark

Fluid balance neutralization secured by hemodynamic monitoring versus protocolized standard of care in critically ill patients requiring continuous renal replacement therapy: study protocol of the GO NEUTRAL randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-022-06735-6

Published Online: 2022-09-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bitker, Laurent http://orcid.org/0000-0002-4698-053X
Pradat, Pierre

Dupuis, Claire

Klouche, Kada

Illinger, Julien

Souweine, Bertrand

Richard, Jean-Christophe
Funding

Funding for this research was provided by:

French Ministry of Health (Inter-regional Hospital Clinical Research Program 2019)
License Information

Text and Data Mining valid from 2022-09-22

Version of Record valid from 2022-09-22
More Information

Article History

Received: 26 August 2022

Accepted: 12 September 2022

First Online: 22 September 2022

Declarations

:

: The GO NEUTRAL study (protocol version 1) was approved by a human research ethics committee (Comité de Protection des Personnes Sud-Méditerranée I) on April 29, 2021, under the reference number IDRCB 2021-A00692-39 (Supplemental Material InternalRef removed for the French and English versions). The trial received authorization to start from the French regulatory agency (Agence National de Sécurité du Médicament) on May 27, 2021.Written informed consent will be obtained from all participants and/or their legal representative if the participant is in a medical condition that does not allow informed consent. A model consent form will be provided upon request to the corresponding author.

: Not applicable. No clinical details of trial participants are presented in the present article or will be presented in reports of the trial results.

: The authors declare they have no competing interests.

Document is current

Any future updates will be listed below